Novel role of NLRP3-inflammasome in regulation of lipogenesis in fasting-induced hepatic steatosis

This article was published in the following Dove Press journal:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Baoqing Liu¹
Xiaoxiang Mao^{2,3}
Dandan Huang^{2,3}
Fei Li¹
Nianguo Dong¹

¹Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; ²Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; ³Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China

→ Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: <https://youtu.be/v46uHmzb4I>

Correspondence: Fei Li; Nianguo Dong
1277 Jiefang Ave, Wuhan, Hubei, 430000,
People's Republic of China
Email lifeli_union@sina.com;
dongnianguo@sina.com

Background: The liver coordinates a series of metabolic adaptations to maintain the energy balance of the system and provide adequate nutrients to key organs, tissues and cells during starvation. However, the mediators and underlying molecular mechanisms that mediate these fasting-induced adaptive responses remain unclear.

Materials and methods: Male wild-type C57BL/6J littermates (8-weeks-old) were intra-peritoneally injected with MCC950 or vehicle, and then randomly divided into three groups: fed, fasted, and refed. Plasma IL1 β and insulin levels were detected by ELISA kits. Plasma and hepatic metabolites were determined using commercial assay kits. HepaRG cell line was applied to verify the regulation of NLRP3 on lipogenesis.

Results: NOD-like receptor protein 3 (NLRP3) and its downstream inflammatory cytokines were significantly suppressed after 24 h fasting and recovered upon 6 h refeeding in plasma and liver tissues of mice. Moreover, fasting-induced hepatic steatosis and accompanied liver injury were ameliorated when mice were intraperitoneally injected with MCC950 (a selective NLRP3 inhibitor). Further study revealed that MCC950 suppressed sterol regulatory element-binding protein-1c (SREBP-1c) expression and transcriptional activity, thus inhibited lipogenesis in the liver, which may explain its role in stabilizing lipid metabolism.

Conclusion: The NLRP3 inhibitor-MCC950 protects against fasting-induced hepatic steatosis. The novel and critical role of NLRP3 in lipogenesis may explain its importance in regulating the adaptive responses of the liver upon starvation stress and may provide therapeutic value.

Keywords: metabolic homeostasis, starvation stress, NLRP3, MCC950, SREBP-1c

Introduction

The deregulation of metabolic homeostasis leads to metabolic disorders such as fatty liver disease, obesity and diabetes.^{1,2} The liver functions as a major metabolic regulator for maintaining metabolic homeostasis, allowing extrahepatic tissues such as adipose and muscle to function normally under overnutrition or starvation.^{3–5} During starvation, the liver coordinates a series of metabolic adaptations to maintain the energy balance of the system and provide adequate nutrients to key organs, tissues and cells.^{6,7} These regulatory mechanisms in the liver include supplying glucose to the circulation, initially from hepatic glycogen and then by gluconeogenesis produced from other non-carbohydrate materials.⁸ In a sustained fasting state, ketones are synthesized by the liver to provide an energy source to replace glucose for high-oxygen consuming tissues.^{9,10} Fatty acid oxidation is considered to be critical for providing ATP and NADP to facilitate glycogenesis and acetyl-CoA for ketogenesis.^{11,12} Accumulating studies

have revealed that many molecules participate in regulating hepatic metabolism during fasting or other physiological states, including sterol regulatory element-binding protein-1c (SREBP-1c),¹³ peroxisome proliferator-activated receptor- α ,^{5,14} glucocorticoid receptor, cAMP responsive element binding protein 1, and CCAAT/enhancer binding protein beta.¹⁵ It would be valuable to discover novel mediator(s) to further understand the regulation of liver function upon starvation stress.

NOD-like receptor protein 3 (NLRP3)-inflammasomes, composed of NLRP3, adapter protein ACS and procaspase 1, is an important regulator of the activation of caspase1 and the maturation of IL1 β . It can be activated by multiple mediators, including metabolic disturbance.^{16,17} Previous studies mainly discussed the function of NLRP3 in macrophages where it is abundantly expressed. During the last few years, researchers indicated that NLRP3 inflammasome is closely related to the pathogenesis of most acute and chronic liver injuries,^{18,19} increased expression of hepatic NLRP3, ACS and caspase-1 accompanies with liver inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, which suggests a strong link between NLRP3 inflammasomes and hepatic dysfunction. Although NLRP3 inflammasome is highly expressed in liver, the regulatory mechanism of NLRP3 inflammasome on lipid synthesis, fatty acid oxidation, and transport in hepatocytes remains unknown.

In the present study, we discovered that the NLRP3 is involved in the regulation of fasting-induced hepatic steatosis and hepatic lipogenesis in hepatocytes. Its inhibitor MCC950 restrained SREBP-1c expression and transcriptional activation and reduced lipogenesis-associated gene expression, which suggests that NLRP3 is a critical regulator of metabolic homeostasis upon starvation stress.

Materials and methods

Animals and treatment

Male wild-type C57BL/6J littermates (8-weeks-old) were randomly divided into three groups: fed, fasted, and refed, as described previously.²⁰ The fed group was fed a normal chow diet; the fasted group was fasted for 24 hrs; and the refed group was fasted for 24 hrs, followed by 6 hrs of refeeding prior to the end of the experiment. MCC950 or vehicle was administered intraperitoneally at a dose of 10 mg/kg prior to diet deprivation or refeeding. The animals were housed in standard cages at 22°C in a 12/12-hrs

light/dark cycle. When the mice were sacrificed, blood samples were collected, and tissues were taken rapidly and fixed or stored in liquid nitrogen. All animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Ethical Committee of Huazhong University of Science and Technology.

Western blot analysis

Tissue samples were lysed at 4°C with RIPA buffer containing protease and phosphatase inhibitors. Forty micrograms of protein, as measured by a standard bicinchoninic acid assay (BSA) kit, were loaded onto 10% SDS-polyacrylamide gels for electrophoresis. Then, proteins were transferred to polyvinylidene difluoride membranes and blocked with 5% dry milk for 2 hrs at room temperature. Next, the membranes were probed with primary antibodies overnight at 4°C and incubated with secondary horseradish peroxidase antibodies for 1 hrs. Subsequently, the proteins were detected with a Bio-Rad (Hercules, CA, USA) imaging system. The following antibodies were used: β -tubulin (1:1,000 dilution, ab6046, Abcam), NLRP3 (1:1,000 dilution, 15101, Cell Signaling Technology), Caspase1 (1:1,000 dilution, NBP1-45433, Novus), IL1 β (1:1,000 dilution, 12242, Cell Signaling Technology), FASN (1:1,000 dilution, 3180, Cell Signaling Technology), ACC1 (1:1,000 dilution, 4190, Cell Signaling Technology), and SREBP-1c (1:1,000 dilution, ab28481, Abcam).

ELISA

The concentration of IL1 β in plasma was measured by ELISA kits (MLB00C, R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Absorbance at 450 nm was measured using a microplate reader (Thermo Fisher Scientific), and the 450 nm absorbance values were corrected by subtracting the reading at 570 nm.

Measurement of plasma and hepatic metabolites

Blood glucose concentrations were determined using a glucometer. Mouse plasma insulin was measured with an ultrasensitive mouse insulin ELISA kit (Millipore, Billerica, MA, USA). Liver lipid contents were extracted as previously described,²¹ Plasma and liver triglyceride

and cholesterol levels were detected using commercial assay kits [290–63,701 and 294–65,801 for triglyceride and cholesterol, respectively; Wako, Osaka, Japan] according to the manufacturer's instructions.

Oil red O staining

Livers were immersed in OCT and kept at -80°C until use. After 5 mins of drying, frozen sections were incubated with oil red O, washed with 60% isopropanol, and counterstained with Mayer's hematoxylin and saturated lithium carbonate. The images were captured on a light microscope.

Quantitative real-time qPCR

Tissue samples were homogenized with TRIzol reagent (Invitrogen, USA); total RNA was isolated and treated with RNase-free DNase to remove genomic DNA, and then reverse transcribed into cDNA by using a PrimeScript RT reagent kit (Takara, China). Real-time qPCR was performed using an ABI 7500 real-time PCR system and SYBR Green PCR Master Mix (Takara, China) in duplicate. StepOne Software v2.3 (Applied Biosystems, Waltham, MA, USA) was used to analyze the results with the $2^{-\Delta\Delta\text{CT}}$ -method after normalization to β -actin levels (18s was used to determine that β -actin does not change between groups; Figure S1).

The primers applied to real-time qPCR were as follows:

18S-Forward: 5'-TTGACGGAAGGGCACCACCAG-3'; 18S-Reverse: 5'-GCACCACCACCCACGGAATCG-3'; β -actin-Forward: 5'-AACAGTCCGCCTAGAAGCAC-3'; β -actin-Reverse: 5'-CGTTGACATCCGTAAAGACC-3'; IL1 β -Forward: 5'-GAAATGCCACCTTTTGACAGTG-3'; IL1 β -Reverse: 5'-TGGATGCTCTCATCAGGACAG-3'; SREBP1c-Forward: 5'-GCAGCCACCATCTAGCCTG-3'; SREBP1c-Reverse: 5'-CAGCAGTGAGTCTGCCTTGAT-3'; FASN-Forward: 5'-GGAGGTGGTGATAGCCGGTAT-3'; FASN-Reverse: 5'-TGGGTAATCCATAGAGCCCAG-3'; ACC1-Forward: 5'-ATGGGCGGAATGGTCTCTTTC-3'; ACC1-Reverse: 5'-TGGGGACCTTGTCTTCATCAT-3'; ACOX-Forward: 5'-TAACTTCCTCACTCGAAGCCA-3'; 18S-Reverse: 5'-AGTTCCATGACCCATCTCTGTC-3'; CPT1a-Forward: 5'-TGGCATCATCACTGGTGTGTT-3'; 18S-Reverse: 5'-GTCTAGGGTCCGATTGATCTTTG-3'; MCAD-Forward: 5'-AGGGTTTAGTTTTGAGTTGACG-3'; 18S-Reverse: 5'-CCCCGCTTTTGTCATATCCG-3'; CD36-Forward: 5'-ATGGGCTGTGATCGGAAGTAC-3'; 18S-Reverse: 5'-GTCTTCCCAATAAGCATGTCTCC-3'; FABP1-Forward: 5'-ATGAACTTCTCCGGCAAGTACC-

3'; 18S-Reverse: 5'-CTGACACCCCCTTGATGTCC-3'; DGAT1-Forward: 5'-TCCGTCCAGGGTGGTAGTG-3'; 18S-Reverse: 5'-TGAACAAAGAATCTTGCAGACGA-3';

Cell line and culture

HepaRG cells (HepaRG10) were purchased from Gibco (Thermo Fisher Scientific, Waltham, MA, USA) and cultured as described in the manufacturer's instructions. Cells were cultured at 37°C with 5% CO_2 in a humidified atmosphere. After 24 hrs of serum starvation, the cells were treated as described below.

Luciferase reporter assays

A human SREBP-1c promoter-driven luciferase plasmid encoding a 5'-flanking fragment of the SREBP-1c ($-1005/+24$) promoter was described previously.²² Transfections in HepaRG cells were performed in triplicate in 24-well plates. After overnight starvation, 250 ng of SREBP-1c promoter reporter plasmids or empty vector, together with pRL-TK encoding Renilla luciferase, were co-transfected by using Lipofectamine 2000. After transfection, cells were treated with 250 μM BSA-conjugated palmitic acid (P5585, Sigma, St Louis, MO, USA) or vehicle, in the presence or absence of MCC950. Luciferase activity was measured 24 hrs later using a Dual-Luciferase Reporter Assay System (Promega, Fitchburg, WI, USA), and normalized to Renilla luciferase activity.

Chromatin immunoprecipitation (ChIP)

Chromatin immunoprecipitation (ChIP) experiments were performed exactly as described previously.^{23,24} Liver tissues were subjected to cross-linking with 1% formaldehyde before the preparation of nuclear extracts. Chromatin-SREBP-1c complexes were immunoprecipitated with anti-SREBP-1c or rabbit IgG (Cell Signaling Technology) by incubation at 4°C overnight on a rocking platform, and then were incubated with the beads from the ChIP kit at 4°C for 2 hrs with gentle rocking. After washing sufficiently with the washing buffer, the complexes were eluted with the elution buffer from the beads, and the extracted DNA from the final step was quantified by PCR to amplify the FASN and ACC1 promoters. The primers were as follows: mouse FASN: forward, 5'-TCACATCAGGGGACAGTTAG-3'; reverse, 5'-TAAGCAAATAGAGAACTCCC-3'; mouse ACC1: forward, 5'-GTCCCGCCTCCTCCAGT-3'; reverse, 5'-GACTTCAGAGCCCACCGAC-3'; The raw Ct values of the ChIP samples were divided by the Ct values of the

relevant input samples, and the values were presented as the percentage of the input values (% input).

Statistical analysis

GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis. Band densitometry of the Western blot images was quantified with ImageJ Software. All data are presented as the mean $\pm$ SEM. Comparisons between two groups were conducted by Student's *t* test, and one-way ANOVA was used to assess the statistical significance among multiple groups. $P < 0.05$ was considered statistically significant. All data are representative of three independent experiments.

Results

The NLRP3-inflammasome is inhibited by nutrient deprivation and triggered by refeeding

To investigate whether the NLRP3-inflammasome is involved in fasting-induced hepatic steatosis, we measured hepatic NLRP3, pro-casp1, active casp1, pro-IL1 β and active IL1 β

expression levels. We found that NLRP3, active casp1 and IL1 β were decreased after 24 hrs of fasting and recovered upon refeeding in mice (Figure 1A). Meanwhile, the mRNA and plasma levels of IL1 β showed a parallel change (Figure 1B-C). These data indicate the potential role of the NLRP3-inflammasome in fasting-induced hepatic steatosis.

MCC950 effectively inhibits IL1 β secretion and ameliorates fasting-induced hepatic lipid deposition

To explore whether inhibition of the NLRP3-inflammasome plays a role in fasting-induced lipid instability, we treated mice with MCC950 prior to diet deprivation or refeeding. As shown in Figure 2A, the circulating IL1 β levels were increased by refeeding and were significantly decreased by MCC950 compared to that of vehicle. MCC950 administration increased blood glucose levels both in fasted mice and refed mice, while without having an impact on plasma insulin levels (Figure 2B). In the liver, fasting-induced lipid deposition was significantly ameliorated by administration of MCC950, as confirmed by the macroscopic appearance of

Figure 1 NLRP3-inflammasome is inhibited by nutrient deprivation and triggered by refeeding. (A) Western blot and densitometric analysis for NLRP3, active-casp1 and IL1 β in liver of fed, fasted, and refed mice, with $n=6$ per group. (B) Relative mRNA levels of IL1 β in liver of fed, fasted, and refed mice, with $n=8$ per group. (C) ELISA assay detected plasma levels of IL1 β in fasting and refeeding mice, with $n=8$ per group. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ compared to the fed group; # $P < 0.05$, ## $P < 0.01$ and ### $P < 0.001$ compared to the fasted group.

Figure 2 MCC950 effectively inhibits IL1 β secretion and ameliorates fasting-induced hepatic lipid deposition. **(A)** Plasma levels of IL1 β were decreased by MCC950 administration. **(B)** Blood glucose and plasma insulin levels in vehicle or MCC950 treated mice after fasting for 24 hrs or followed by *n*6 h-refeeding. **(C)** Hepatic macroscopic appearance of different groups. **(D)** Representative Oil red O staining of frozen liver sections. Hepatic and plasma triglyceride, the scale bar is 100 μ m. **(E)** and **(F)** levels in vehicle or MCC950 treated mice after fasting or refeeding. *n*=8 per group. ** *P*<0.01 compared to the fasted group treated with vehicle, # *P*<0.05 and ### *P*<0.01 compared to the vehicle group under the same diet treatment.

the liver and Oil red O staining (Figure 2C and D). Further quantitative analysis revealed that MCC950 reduced the triglyceride content in liver but not in plasma compared to that of the vehicle (Figure 2E). However, there were no significant changes in cholesterol levels between the different groups (Figure 2F). The results show that the inhibition of NLRP3 largely reduced hepatic lipid deposition.

MCC950 alters the expression of key genes related to lipogenesis in the liver

To examine the latent mechanism of MCC950 on hepatic steatosis, we examined metabolic-associated genes in the liver. Real-time qPCR revealed that lipogenesis-related genes (eg, SREBP-1c, FASN, and ACC1) were suppressed in the MCC950 group compared to those of the vehicle group both in fasted and refeed mice (Figure 3A), while fatty acid utilization-related genes (eg, ACOX, CPT1a, and MCAD)

were unaltered by MCC950 treatment (Figure 3B). However, genes related to fatty acid transportation (eg, CD36, and FABP1) or esterification (eg, DGAT1) showed no consistent changes either in starvation or refeeding (Figure 3C-D). Therefore, the improvement of MCC950 on fasting-induced hepatic steatosis is mainly through the amelioration of intra-hepatic lipogenesis.

MCC950 suppressed SREBP-1c expression and its regulatory effect on lipogenesis

To further delineate the mechanisms responsible for the phenotype in MCC950 challenged mice, the levels of proteins involved in lipogenesis were examined. As shown in Figure 4A-B, the nuclear form and precursor of SREBP-1c were increased upon refeeding, while MCC950 treatment remarkably inhibited the expression of the nuclear form and precursor

Figure 3 MCC950 alters the expression of key genes related to lipogenesis in the liver: **(A)** Hepatic lipogenesis-related genes such as SREBP-1c, FASN, and ACC1 were acutely induced by refeeding and inhibited in MCC950 treated mice. **(B-D)** Effects of MCC950 treatment on fatty acid β -oxidation (ACOX, CPT1 α , and MCAD), transportation (CD36, and FABP1), and esterification (DGAT1) compared to that of vehicle-treated group. n=8 per group. * $P<0.05$, ** $P<0.01$, *** $P<0.001$, and **** $P<0.0001$ compared to the fasted group treated with vehicle, # $P<0.05$ and ##### $P<0.0001$ compared to the vehicle group under the same diet treatment.

of SREBP-1c both in fasted and refed state. Accordingly, the target genes of SREBP-1c (eg, ACC1, and FASN) were also attenuated by MCC950 treatment (Figure S2). In vitro, NLRP3-inflammasome can be activated by PA and inhibited by MCC950 (Figure S3). To further confirm the role of MCC950 on SREBP-1c, we detected an effect of MCC950 on SREBP-1c transcriptional activity which was induced by PA in HepaRG cells using a luciferase reporter gene assay. As shown in Figure 4C, SREBP-1c promoter activity was inhibited by MCC950 in a dose-dependent manner. In addition, the binding of SREBP-1c to its target genes (eg, FASN and ACC1) was slightly decreased during starvation, while prominently reduced after refeeding, as analyzed by the ChIP assay in the liver tissues of mice (Figure 4D). Collectively, these results indicate that MCC950 inhibits SREBP-1c expression and transcriptional activity, suppresses lipogenesis-related

genes expression, thus ameliorates nutrient instability-induced steatosis.

Discussion

Mammals have developed multiple mechanisms for accommodating changes in the environment, such as changes in food availability.²⁵ Liver, as the central organ in regulating metabolism,⁴ plays an irreplaceable role in maintaining nutrient stability during starvation and refeeding, and also is subjected to various nutrient stress,²⁶ such as lipotoxic, inflammation.²⁷ NLRP3 is a member of the NLR family, activation of the NLRP3-inflammasome increases caspase1 activation and IL1 β production, which indicate that NLRP3 is an important regulator of the inflammatory response. Recent studies show that activation of the NLRP3-inflammasome is associated with metabolic dysfunction,²⁸

Figure 4 MCC950 inhibits SREBP-1c expression and prevents its regulation on downstream target genes. **(A)** Metabolism-related signaling pathway was detected by Western blot in fasted and re-fed mice challenged with MCC950 or vehicle, with β -tubulin as a loading control. **(B)** Quantitative results of the protein levels of mature or precursors SREBP-1c, Casp1, IL1 β . * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$ compared to the fasted group treated with vehicle, # $P < 0.05$ and ### $P < 0.001$ compared to the vehicle group under the same diet treatment. **(C)** Normalized activities of the luciferase reporters analyzing the effect of MCC950 on SREBP-1c promoter activation which was induced by PA in HepaRG cells. & $P < 0.05$ and && $P < 0.01$. **(D)** Chromatin immunoprecipitation (ChIP) assay using chromatin isolated from livers of mice after fasting or refeeding. Nuclear extracts were immunoprecipitated with an anti-SREBP-1c antibody, and purified DNA was subjected to qPCR by specific primers located at the promoter region of mouse FASN and ACC1. # $P < 0.05$ compared to the re-fed group treated with vehicle.

which provides us with new insight into whether and how NLRP3 can regulate lipid metabolism.

The NLRP3-inflammasome was suppressed during starvation, but was rescued after refeeding, along with the activation of caspase1 and increased maturation of IL1 β . When we intraperitoneally injected the mice with the selective NLRP3 inhibitor MCC950, we observed the amelioration of the fasting-induced liver lipid accumulation, which demonstrated a novel role of NLRP3 in the regulation of fasting-induced hepatic steatosis.

Additionally, we examined several pathways associated with lipid metabolism (lipogenesis, fatty acid oxidation, lipid transportation and esterification) and their effector

molecules. MCC950 significantly inhibited genes expression related to lipogenesis, while the genes involved in fatty acid oxidation, including ACOX, CPT1 α and MCAD showed no obvious changes. This finding suggested that the protective effects of MCC950 in fasting-induced hepatic steatosis and the accompanying metabolic system changes are mainly due to the inhibition of lipogenesis.

SREBP-1c is a master regulator of genes involved in lipogenesis and plays an important regulatory role in lipid metabolism. Further exploring the underlying mechanism of MCC950 in the regulation of hepatic lipogenesis, we detected a reduction of mature form and precursors of SREBP-1c in the liver when injected with MCC950. We

stimulated lipid deposition in vitro using a HepaRG cell line that was treated with palmitic acid^{29,30} and challenged with MCC950, which resulted in the concentration-dependent suppression of SREBP-1c promoter activity in the luciferase assay. Chromatin immunoprecipitation (ChIP) assays of liver tissue also showed that MCC950 remarkably attenuated the transcription of its downstream target genes (FASN and ACC1).

The most important finding of our work is that NLRP3-inflammasome accelerated lipogenesis in hepatocytes, for its inhibitor MCC950 suppressed the transcription activity of SREBP-1c and its target genes FASN and ACC1. Intraperitoneal injection of MCC950 not only affected the activity of NLRP3-inflammasome in hepatocytes, but also inhibited the inflammatory response of kupffer cells (KCs; macrophages in the liver), which is a limitation of our study. Although we demonstrated that MCC950 reduced SREBP-1c transcription while inhibiting NLRP3-inflammasome activation, we do not know whether KCs are involved in this regulatory relationship. The crosstalk between KCs and hepatocytes is worth exploring, and we will do further researches in this field.

In conclusion, our findings establish a new role for NLRP3 and its inhibitor MCC950 in the regulation of lipogenesis and metabolic disorders after exposure to starvation or refeeding. The inhibition of NLRP3 could ameliorate lipid accumulation, liver injury and dyslipidemia, which may prospect its importance in regulating the adaptive responses of the liver upon starvation stress, and provide therapeutic value.

Acknowledgments

This work was supported by National Natural Science Foundation of China (No: 81670351) and Graduates' Innovation Fund, Huazhong University of Science and Technology (No: 5003530056 and 5003530057). Dr Baoqing Liu and Dr Xiaoxiang Mao contributed equally as co-first authors.

Disclosure

The authors report no conflicts of interest in this work.

References

- Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. *Hepatology*. 2010;52(2):774–788. doi:10.1002/hep.23719
- Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*. 2010;52(5):1836–1846. doi:10.1002/hep.24001
- Goedeke L, Bates J, Vatner DF, et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. *Hepatology*. 2018;68(6):2197–2211. doi:10.1002/hep.30097
- Cahill GF Jr. Fuel metabolism in starvation. *Annu Rev Nutr*. 2006;26:1–22. doi:10.1146/annurev.nutr.26.061505.111258
- Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. *J Biol Chem*. 2000;275(37):28918–28928. doi:10.1074/jbc.M910350199
- Xu J, Donepudi AC, Moscovitz JE, Slitt AL, Makishima M. Keap1-knockdown decreases fasting-induced fatty liver via altered lipid metabolism and decreased fatty acid mobilization from adipose tissue. *PLoS One*. 2013;8(11):e79841. doi:10.1371/journal.pone.0079841
- Rouvinen-Watt K, Mustonen AM, Conway R, et al. Rapid development of fasting-induced hepatic lipidosis in the American mink (neovison vison): effects of food deprivation and re-alimentation on body fat depots, tissue fatty acid profiles, hematology and endocrinology. *Lipids*. 2010;45(2):111–128. doi:10.1007/s11745-009-3377-4
- Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. *Diabetes*. 2014;63(12):4064–4075. doi:10.2337/db14-0541
- Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. *IUBMB Life*. 2001;51(4):241–247. doi:10.1080/152165401753311780
- Bae HR, Kim DH, Park MH, et al. beta-hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. *Oncotarget*. 2016;7(41):66444–66454. doi:10.18632/oncotarget.12119
- Cotter DG, d'Avignon DA, Wentz AE, Weber ML, Crawford PA. Obligate role for ketone body oxidation in neonatal metabolic homeostasis. *J Biol Chem*. 2011;286(9):6902–6910. doi:10.1074/jbc.M110.192369
- Lee J, Choi J, Scafidi S, Wolfgang MJ. Hepatic fatty acid oxidation restrains systemic catabolism during starvation. *Cell Rep*. 2016;16(1):201–212. doi:10.1016/j.celrep.2016.05.062
- Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest*. 2002;109(9):1125–1131. doi:10.1172/JCI15593
- Langhi C, Baldan A. CIDEA/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis. *Hepatology*. 2015;61(4):1227–1238. doi:10.1002/hep.27607
- Goldstein I, Baek S, Presman DM, Paakinaho V, Swinstead EE, Hager GL. Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response. *Genome Res*. 2017;27(3):427–439. doi:10.1101/gr.212175.116
- Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. *Hepatology*. 2011;54(1):133–144. doi:10.1002/hep.24341
- Ratsimandresy RA, Dorfleutner A, Stehlik C. An update on PYRIN domain-containing pattern recognition receptors: from immunity to pathology. *Front Immunol*. 2013;4:440. doi:10.3389/fimmu.2013.00440
- Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. *Hepatology*. 2008;48(2):670–678. doi:10.1002/hep.22399
- Gao B. Innate immunity and steatohepatitis: a critical role of another toll (TLR-9). *Gastroenterology*. 2010;139(1):27–30. doi:10.1053/j.gastro.2010.05.018

20. Ponugoti B, Kim DH, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. *J Biol Chem*. 2010;285(44):33959–33970. doi:10.1074/jbc.M110.122978
21. Huang D, Liu B, Huang K, Huang K. Enoyl coenzyme A hydratase 1 protects against high-fat-diet-induced hepatic steatosis and insulin resistance. *Biochem Biophys Res Commun*. 2018;499(3):403–409. doi:10.1016/j.bbrc.2018.03.052
22. Gao LL, Li M, Wang Q, Liu SA, Zhang JQ, Cheng J. HCBP6 modulates triglyceride homeostasis in hepatocytes via the SREBP1c/FASN pathway. *J Cell Biochem*. 2015;116(10):2375–2384. doi:10.1002/jcb.25188
23. Da Silva Xavier G, Rutter GA, Diraison F, Andreolas C, Leclerc I. ChREBP binding to fatty acid synthase and L-type pyruvate kinase genes is stimulated by glucose in pancreatic beta-cells. *J Lipid Res*. 2006;47(11):2482–2491. doi:10.1194/jlr.M600289-JLR200
24. Zhang M, Sun W, Qian J, Tang Y. Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid beta-oxidation and ketogenesis via activating XBP1 signaling in liver. *Redox Biol*. 2018;16:87–96. doi:10.1016/j.redox.2018.01.013
25. Newman JC, Verdin E. beta-hydroxybutyrate: a signaling metabolite. *Annu Rev Nutr*. 2017;37:51–76. doi:10.1146/annurev-nutr-071816-064916
26. Khambu B, Yan S, Huda N, Liu G, Yin XM. Homeostatic role of autophagy in hepatocytes. *Semin Liver Dis*. 2018;38(4):308–319. doi:10.1055/s-0038-1669939
27. Chrysikos D, Mariolis-Sapsakos T, Triantafyllou T, Karampelias V, Mitrousias A, Theodoropoulos G. Laparoscopic abdominoperineal resection for the treatment of a mucinous adenocarcinoma associated with an anal fistula. *J Surg Case Rep*. 2018;2018(3):rjy036. doi:10.1093/jscr/rjy036
28. Traba J, Kwarteng-Siaw M, Okoli TC, et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. *J Clin Invest*. 2015;125(12):4592–4600. doi:10.1172/JCI83260
29. Kanebratt KP, Andersson TB. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. *Drug Metab Dispos*. 2008;36(7):1444–1452. doi:10.1124/dmd.107.020016
30. Brown MV, Compton SA, Milburn MV, Lawton KA, Cheatham B. Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. *Obesity (Silver Spring, Md)*. 2013;21(12):E561–E570. doi:10.1002/oby.20440

Supplementary materials

Figure S1 β-Actin does not differ between groups. Real-time qPCR indicated that housekeeping gene 18S and β-actin do not differ between groups. n=8 per group.

Figure S2 Inhibition of NLRP3-inflammasome reduced the protein level of lipogenesis-related genes. Densitometric analysis for FASN and ACC1 in fasted and refed mice treated with MCC950 or vehicle. * $P < 0.05$, and ** $P < 0.01$ compared to the fasted group treated with vehicle, # $P < 0.05$, ## $P < 0.01$ and ### $P < 0.001$ compared to the vehicle group under the same diet treatment.

Figure S3 The NLRP3-inflammasome can be activated by PA treatment and inhibited by MCC950 in a concentration-dependent way in HepaRG cell line. Western blot of NLRP3 in HepaRG indicated that PA treatment activates NLRP3 inflammasome, which could be suppressed by MCC950.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>